AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 38730030
Drug: Guided and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guided and unguided internet-delivered psychodynamic therapy (IPDT)
Trial: 38730089
Drug: Urosepsis with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urosepsis with multi-drug-resistant (MDR) pathogens
Trial: 38730096
Drug: Perampanel (monotherapy)
RxNorm normalized name: Perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perampanel (monotherapy)
Trial: 38730096
Drug: Perampanel (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perampanel (first adjunctive therapy)
Trial: 38730343
Drug: Serological multiplex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serological multiplex assays based on various antigen targets and antibody properties.
Trial: 38730496
Drug: lecanemab 10
RxNorm normalized name: LECANEMAB 100 mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [LEQEMBI]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lecanemab 10 mg/kg biweekly
Trial: 38730548
Drug: Liver-directed radiotherapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver-directed radiotherapy with escalating functional liver radiation dose constraints (prescription dose 67.5-75 Gy in 15 fractions or 75-100 Gy in 25 fractions)
Trial: 38733160
Drug: Sacubitril/valsartan (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sacubitril/valsartan (titrated to the maximum dose of 97/103 mg twice daily)
Trial: 38733340
Drug: Azathioprine 150
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azathioprine 150 mg/day and hydroxyurea 25 mg/kg/day for 3 months prior to alemtuzumab 1 mg/kg and 300 cGy TBI conditioning
Trial: 38734016
Drug: Doravirine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doravirine (100 mg) and Islatravir (0·75 mg)
Trial: 38734383
Drug: Bulevirtide 2
RxNorm normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Bulevirtide 2 mg/day for 144 weeks
Trial: 38734383
Drug: Bulevirtide 10
RxNorm normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Bulevirtide 10 mg/day for 144 weeks
Trial: 38734383
Drug: Delayed treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed treatment for 48 weeks followed by Bulevirtide 10 mg/day for 96 weeks
Trial: 38735220
Drug: SC trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC trastuzumab (fixed dose 600 mg, q3w) administered through a hand-held syringe followed by 7 cycles of SC trastuzumab administered with an SID
Trial: 38736116
Drug: Golimumab 50
RxNorm normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Golimumab 50 mg subcutaneously every 4 weeks
Trial: 38737002
Drug: Once-weekly subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-weekly subcutaneous semaglutide 1.0 mg
Trial: 38737110
Drug: Lower PHR
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower PHR (PHR-L) with DM
Trial: 38737349
Drug: Transcranial photobiomodulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcranial photobiomodulation (tPBM) - Pulses of near-infrared light (40 Hz, 850 nm) delivered noninvasively twice a week for eight weeks
Trial: 38737600
Drug: Carbon ion
RxNorm normalized name: CARBON ION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon ion radiotherapy (CIRT) with RBE-weighted fraction doses of 8.1-10.5 Gy, total doses 32.4-42.0 Gy, performed every other day in four fractions
Trial: 38737708
Drug: Sustained-release carvedilol
RxNorm normalized name: carvedilol Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release carvedilol (carvedilol-SR)
Trial: 38738598
Drug: Magnesium citrate
RxNorm normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Magnesium citrate 200 mg daily for 8 weeks
Trial: 38739079
Drug: Aficamten (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aficamten (starting dose 5 mg, maximum dose 20 mg)
Trial: 38739123
Drug: High-intensity care
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity care (HIC) - rapid uptitration of heart failure GDMT to 100% of recommended doses within 2 weeks of discharge and 4 scheduled outpatient visits over 2 months after discharge
Trial: 38739306
Drug: Back2School (B2S),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Back2School (B2S), a modular transdiagnostic cognitive behavioral therapy (CBT) for SAPs, with an average of 15.0 hours of intervention (SD=3.9) over three months.
Trial: 38739306
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as Usual (TAU), comprising public and/or private intervention services, with an average of 13.4 hours of intervention (SD=21.6).
Trial: 38739382
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (micronized microencapsulated ferric pyrophosphate), 1 mg/kg, once daily from age 4 to 9 months.
Trial: 38739382
Drug: Placebo (maltodextrin),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (maltodextrin), once daily from age 4 to 9 months.
Trial: 38739422
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of adalimumab-adbm
Trial: 38739615
Drug: State-of-the-art periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: State-of-the-art periodontal treatment during pregnancy
Trial: 38739615
Drug: Periodontal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periodontal treatment after giving birth
Trial: 38739766
Drug: Skin-nerve preparations
RxNorm normalized name: oryctolagus cuniculus nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin-nerve preparations of contusion SCI mice 7 days after injury
Trial: 38740027
Drug: Ritonavir-boosted lopinavir
RxNorm normalized name: lopinavir / ritonavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir-boosted lopinavir (lopinavir 400 mg twice daily + ritonavir 100 mg twice daily)
Trial: 38740027
Drug: Raltegravir (raltegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (raltegravir 400 mg twice daily)
Trial: 38740027
Drug: Triple nucleoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple nucleoside reverse transcriptase inhibitor (NRTI) group (tenofovir 245 mg once daily + emtricitabine 200 mg once daily + zidovudine 250 mg twice daily)
Trial: 38740030
Drug: Pembrolizumab 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 200 mg intravenously every 3 weeks for a maximum of 35 cycles
Trial: 38740499
Drug: Low-dose naltrexone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose naltrexone (LDN) starting at 1 mg daily, up-titrated to 4.5 mg daily or maximum tolerated dose over 16 weeks.
Trial: 38740499
Drug: Placebo starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo starting at 1 mg daily, up-titrated to 4.5 mg daily or maximum tolerated dose over 16 weeks.
Trial: 38740532
Drug: High-intensity care
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity care (HIC) consisting of rapid up-titration of guideline-directed medical therapy (GDMT) and close follow-up
Trial: 38741375
Drug: Retreatment with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retreatment with immune checkpoint inhibitors (ICIs)
Trial: 38741607
Drug: rhPTH(1-84) 50
RxNorm normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhPTH(1-84) 50 μg once daily, adjusted based on albumin-corrected serum calcium levels
Trial: 38741607
Drug: rhPTH(1-84) 50
RxNorm normalized name: rhPTH
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: rhPTH(1-84) 50 μg once daily
Trial: 38743075
Drug: Intra-operative injection
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-operative injection of bupivacaine into the obturator membrane
Trial: 38743248
Drug: Non-surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical periodontal treatment for periodontitis
Trial: 38743265
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) - 8 weekly sessions
Trial: 38743265
Drug: Whole-Body Hyperthermia
RxNorm normalized name: Insects (whole body), mite dermatophagoides farinae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-Body Hyperthermia (WBH) - 8 weekly sessions
Trial: 38743265
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) and Whole-Body Hyperthermia (WBH) combined
Trial: 38743716
Drug: Prison treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prison treatment as usual (Control)
Trial: 38743958
Drug: Gestational age-based
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestational age-based dosing of UFH (5,000 units subcutaneously every 12 hours in first trimester; 7,500 units in second trimester; 10,000 units in third trimester)
Trial: 38743958
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of UFH (5,000 units subcutaneously every 12 hours)
Trial: 38743958
Drug: Gestational age-based
RxNorm normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gestational age-based dosing of UFH
Trial: 38743958
Drug: Standard dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dosing of UFH
Trial: 38744144
Drug: Quizartinib (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quizartinib (30 mg, 40 mg, or 60 mg) in combination with azacitidine
Trial: 38744460
Drug: First Disease-Modifying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First Disease-Modifying Therapy (DMT)
Trial: 38744844
Drug: ARCT-154 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARCT-154 vaccine (two doses, 28 days apart)
Trial: 38744844
Drug: ARCT-154 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARCT-154 vaccine
Trial: 38745011
Drug: PR006 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PR006 gene therapy
Trial: 38745158
Drug: Concentrated transdiagnostic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated transdiagnostic and micro choice-based group treatment
Trial: 38745322
Drug: Video Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Video Therapy (VT)
Trial: 38745333
Drug: Preoperative hypofractionated
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative hypofractionated proton beam therapy (PBT) - 30 Gy radiobiological equivalent in 5 fractions delivered every other day.
Trial: 38745983
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of indocyanine green (ICG) fluorescence imaging
Trial: 38746205
Drug: TELESCOPE intervention:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TELESCOPE intervention: telehealth decision coaching session about LCS delivered by trained patient navigators, with a low-dose CT scan (LDCT) order placed for each patient wanting LCS.
Trial: 38746220
Drug: Ribociclib 800mg
DrugBank: Ribociclib (DB11730)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ribociclib 800mg daily plus Gemcitabine 1000mg/m2
Trial: 38747162
Drug: NBO-2h group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBO-2h group (10 L/min for 2 hours)
Trial: 38747162
Drug: NBO-4h group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBO-4h group (10 L/min for 4 hours)
Trial: 38747162
Drug: NBO-6h group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NBO-6h group (10 L/min for 6 hours)
Trial: 38747162
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (1 L/min oxygen for 4 hours)
Trial: 38747515
Drug: Telephone Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone Wound Healing Questionnaire (WHQ) administered at 27 to 30 postoperative days.
Trial: 38748319
Drug: EDP1815 (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDP1815 (8 × 10^9 CFU daily)
Trial: 38748321
Drug: Lemborexant (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lemborexant (both doses)
Trial: 38748345
Drug: Crisaborole ointment
RxNorm normalized name: Crisaborole Ointment
DrugBank: Crisaborole (DB05219)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crisaborole ointment 2%
Trial: 38748431
Drug: Bariatric surgery
RxNorm normalized name: Optisource Post Bariatric Surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bariatric surgery in women with baseline insulin levels above median 15.8 μIU/L
Trial: 38748431
Drug: Bariatric surgery
RxNorm normalized name: Optisource Post Bariatric Surgery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bariatric surgery in women with baseline insulin levels below median 15.8 μIU/L
Trial: 38748598
Drug: Bridging intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging intravenous thrombolysis (IVT) before endovascular therapy (EVT)
Trial: 38748598
Drug: Direct endovascular
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct endovascular therapy (EVT) alone
Trial: 38749024
Drug: 6-week internet
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week internet intervention program based on acceptance and commitment therapy principles
Trial: 38749259
Drug: Intranasal dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal dexmedetomidine (2.5 μg/kg initial dose, 1 μg/kg repeat dose if needed 30 min later)
Trial: 38749592
Drug: Low-dose prasugrel
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose prasugrel (3.75 mg/d) monotherapy
Trial: 38749592
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) with low-dose prasugrel and aspirin
Trial: 38749682
Drug: Non-invasive or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive or minimally invasive biospecimens collection (saliva, buccal cells, dried blood spots, urine)
Trial: 38749694
Drug: Biologics for
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologics for CRSwNP
Trial: 38750162
Drug: diet plus
RxNorm normalized name: Glucomannan/Grapefruit Extract/Pyridoxine Oral Tablet [GRAPEFRUIT DIET PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diet plus phytosterol (2.6 g in 2 doses, with meals)
Trial: 38750351
Drug: Senaparib 100
RxNorm normalized name: Senaparib
DrugBank: Senaparib (DB17163)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senaparib 100 mg orally once daily for up to 2 years
Trial: 38750375
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene training (OHt) with toothbrush and dental floss
Trial: 38750398
Drug: Glucose analogue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose analogue PET agent
Trial: 38750518
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy with post-isometric relaxation exercises (Group B)
Trial: 38750518
Drug: Massage therapy
RxNorm normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage therapy alone (Group A)
Trial: 38750866
Drug: Vonoprazan 10
RxNorm normalized name: vonoprazan 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 10 mg vs Placebo
Trial: 38750866
Drug: Vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vonoprazan 20 mg vs Placebo
Trial: 38750866
Drug: All study
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All study arms (including both doses of vonoprazan and placebo)
Trial: 38750870
Drug: Ustekinumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (6 mg/kg intravenously at baseline, then 90 mg subcutaneously every 8 weeks)
Trial: 38751442
Drug: Atezolizumab (1,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1,200 mg)
Trial: 38751523
Drug: Margetuximab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Margetuximab (15 mg/kg over at least 120 minutes) plus chemotherapy
Trial: 38751523
Drug: Trastuzumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (6 mg/kg over at least 30 minutes) plus chemotherapy
Trial: 38751579
Drug: Ashtanga Vinyasa
RxNorm normalized name: Vincasar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ashtanga Vinyasa Yoga Supta Method (AVYSM) - 12 weeks, two weekly one-hour yoga sessions
Trial: 38751852
Drug: Subfascial platelet-rich
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subfascial platelet-rich plasma (PRP) injection
Trial: 38752013
Drug: Cranberry extract
RxNorm normalized name: CRANBERRY EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry extract (1000 mg/day)
Trial: 38752311
Drug: Intrapartum azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrapartum azithromycin (2 g)
Trial: 38752352
Drug: Sildenafil 80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 80 mg TID
Trial: 38752418
Drug: Inspiratory training
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inspiratory training treatment plan (Powerbreathe Plus®) combined with aerobic exercise and olfactory gustatory treatment for 31 days
Trial: 38752418
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy for 31 days
Trial: 38752431
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion (CIVI) of Ketamine, starting at .05 mg/kg/hour and increased to .5 mg/kg/hour as needed over 5 days.
Trial: 38752592
Drug: Continuous-dose abrocitinib
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Continuous-dose abrocitinib (200 mg)
Trial: 38752592
Drug: Reduced-dose abrocitinib
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Reduced-dose abrocitinib (100 mg)
Trial: 38752650
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment to lower systolic blood pressure (target range, 130 to 140 mm Hg)
Trial: 38752802
Drug: pentavalent vaccine
RxNorm normalized name: rotavirus, live, pentavalent vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pentavalent vaccine (DTwP-HB-Hib)
Trial: 38752802
Drug: hexavalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hexavalent vaccine (DTaP-IPV-HB-Hib)
Trial: 38752972
Drug: Culprit-only treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culprit-only treatment (n = 903 nonculprit vessels from 685 patients)
Trial: 38753093
Drug: Intraoperative photodynamic
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative photodynamic therapy (PDT) with 5-ALA HCl, single 200 J/cm
Trial: 38753174
Drug: Supplemental β-carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental β-carotene (15 mg)
Trial: 38753331
Drug: Music Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Therapy (MT) with Standard Care (SC)
Trial: 38753331
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Care (SC) at NICU and postdischarge Music Therapy (MT)
Trial: 38753331
Drug: Music Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music Therapy (MT) at both NICU and postdischarge
Trial: 38753415
Drug: Individualized 12-week
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized 12-week health education program targeting an active lifestyle after oncology treatments.